Patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis or juvenile chronic arthritis that is unresponsive to standard diseasemodifying antirheumatic drugs can now be treated with tumour necrosis factor inhibitors. These biological drugs all antagonise the actions of tumour necrosis factor, a key cytokine central to the inflammatory cascade. Their adverse effects can be severe and include sepsis, reactivation of pulmonary tuberculosis, blood dyscrasias, demyelinating syndromes, lymphoproliferative disease and precipitation of cardiac failure. Careful monitoring of patients is important.
Introduction
In recent years the treatment of inflammatory joint diseases has undergone a dramatic change with the advent of biological drugs. Patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile chronic arthritis are potential candidates for this new therapy. Biological drugs are usually prescribed if the patient's condition has been resistant to treatment with standard disease-modifying antirheumatic drugs or if the patient has been unable to tolerate them. 1 In clinical trials biological drugs have been superior to disease-modifying antirheumatic drugs in achieving disease remission and retarding bony destruction. The most common biological drugs used today belong to the class known as tumour necrosis factor (TNF) inhibitors. This class includes infliximab, adalimumab and etanercept. As these drugs are being used more frequently, it is important to be familiar with the principles of managing patients during treatment in the community.
Mechanism of action
Tumour necrosis factor is a critical pro-inflammatory cytokine in the cascade of inflammatory joint diseases. 2 
Administration of TNF inhibitors
Infliximab is given by intravenous infusion while adalimumab and etanercept are self-administered as subcutaneous injections (Table 1) . For rheumatoid arthritis infliximab is commenced at 3 mg/kg of body weight at 0, 2 and 6 weeks, then every 8 weeks.
(In patients with an incomplete response, the maintenance dose may be gradually increased to a maximum of 10 mg/kg.) The dose of adalimumab is 40 mg fortnightly, while etanercept is given at 25 mg twice weekly or 50 mg once a week. 
Before treatment
As part of the pre-treatment assessment, patients should have a chest X-ray to exclude latent pulmonary tuberculosis and congestive cardiac failure. The full blood count, liver function tests, hepatitis B and C serology, inflammatory markers (CRP, ESR), and anti-nuclear and anti-double-stranded DNA autoantibodies should be checked before therapy. The presence of latent pulmonary tuberculosis warrants eradication therapy, usually for nine months, before starting a TNF inhibitor. This is best managed by a physician experienced in tuberculosis care.
Adverse effects
Given that TNF inhibitors are relatively new drugs, their long-term safety is still being established. From their mechanism of action it is predicted that there will be an increase in the incidence of infection and possibly secondary malignancy. 
Lymphoproliferative disease
Cases of lymphoma have been reported in patients taking TNF inhibitors. The incidence of lymphoma and leukaemia is already increased in patients with rheumatoid arthritis, particularly those with high disease activity. Epidemiological studies differ on whether there is an additional risk of lymphoproliferative disorders among patients with rheumatoid arthritis who are treated with TNF inhibitors. 6, 7 There is no indication that patients with rheumatoid arthritis taking TNF inhibitors are at increased risk of other tumours.
Blood dyscrasias
Medically significant thrombocytopenia and leucopaenia have been reported with TNF inhibitors. However, pancytopaenia including aplastic anaemia rarely occurs. These abnormalities are generally reversible upon cessation of the drug.
Lupus-like autoimmune responses
Positive antinuclear antibodies develop in over 50% of patients with rheumatoid arthritis during treatment with infliximab and 13% develop antibodies to double-stranded DNA. 8 With etanercept, 11% of patients develop a new antinuclear antibody and 2% develop double-stranded DNA antibodies. 9 Despite the high rate of autoantibodies, clinical manifestations of drug-induced systemic lupus erythematosis are rare.
Demyelinating syndromes
Exacerbations of previously quiescent multiple sclerosis and the onset of other demyelinating diseases (such as optic neuritis) have been reported in patients taking TNF inhibitors. Symptoms included paraesthesia, visual disturbance and confusion.
Cardiac failure
Patients with heart failure have elevated concentrations of TNF.
Trials of etanercept and infliximab in heart failure were stopped early because there was no evidence that TNF inhibitors were of benefit. In the case of infliximab, mortality increased. 10 TNF inhibitors are therefore contraindicated in patients with heart failure (New York Heart Association class III and IV).
Pregnancy and lactation
There are no clinical data for pregnant or lactating women being treated with TNF inhibitors. Animal studies were inconclusive with regard to the embryofetal toxicity so their use during pregnancy is not recommended. Women of childbearing age should be advised to use effective contraception during therapy.
Practice points (Box 2)
Before starting a patient on TNF inhibitors, immunisations should be brought up to date. Live vaccines should not be given to people receiving TNF inhibitors. There is no contraindication to yearly influenza and five-yearly pneumococcal vaccination. The book can be read slowly in 90 minutes and this would be time well spent by candidates for postgraduate exams, advanced trainees in general and thoracic medicine, respiratory scientists and nurses. There are good references for further study and an excellent index. Whether it will be carried around in many pockets is another matter, but it is a compact reference which deserves a wide readership.
